The Valeant Pipeline - Our Medicines in Development

Valeant's development pipeline strategy comprises both new compounds as well as product life cycle management. In September 2010, Valeant Pharmaceuticals merged with Biovail Corporation to form a new company, Valeant Pharmaceuticals International Inc. Today, the new company's pipeline combines both company's' promising early and late-stage drug candidates that have unique formulations and mechanisms of action that addresses the need for new treatment regimens for epilepsy, central nervous system diseases such as Parkinson's disease, pain management, and four new dermatology compounds for topical anti-fungals, rosacea and oral acne. Valeant also plans to strategically expand its pipeline by adding new compounds and product extensions through company and product acquisitions.